Redeye maintains its optimistic outlook post the Q1 2024 report despite slightly lower sales and profitability than expected. The surprisingly strong order intake confirms product-market fit and increases the likelihood of significant orders from the European market. Our Base case remains intact at SEK1.4, with considerable upside potential in the share price highlighted

https://www.redeye.se/research/997167/heliospectra-convincing-order-intake-validates-product-market-fit?utm_source=finwire&utm_medium=RSS

Redeye